Acute coronary syndrome (ACS) is an
|
|
- Gwen Poole
- 5 years ago
- Views:
Transcription
1 OVERVIEW OF MEDICAL MANAGEMENT OF ACUTE CORONARY SYNDROMES Robert B. Parker, PharmD * Acute coronary syndrome (ACS) is an umbrella term used to describe any group of symptoms of acute myocardial ischemia (ie, chest pain caused by insufficient blood supply to the heart muscle) that are often caused by atherosclerotic coronary artery disease. Patients experiencing ACS include those patients with disorders that are based on whether ST-segment elevation is present on the electrocardiogram (ECG); patients with ST-elevation are thought to have ST-elevation myocardial infarction (STEMI), whereas patients without ST-elevation may have non ST-segment elevation myocardial infarction (NSTEMI) or unstable angina (UA). Although these are 3 distinct disorders, they share a common pathophysiologic origin characterized by disruption or rupture of the fibrous cap of a vulnerable atherosclerotic plaque. This plaque disruption exposes substances within the plaque that promote thrombus formation. The resultant thrombus then occludes the coronary artery and decreases blood flow to the heart muscle downstream from the thrombus. Patients with STEMI typically have complete thrombotic occlusion of a coronary artery, whereas patients with NSTEMI or UA often have incomplete occlusion of the infarct-related vessel. Unstable angina/non ST-segment elevation myocardial infarction are often considered to be closely related conditions, but of differing severity. The level of severity is determined by whether ischemia is sufficient to cause myocardial damage, as determined by the presence of biomarkers of myocardial injury, such as troponin I, troponin T, or creatine phosphokinase-mb (CK-MB). Patients presenting with clinical symptoms of ACS with *Associate Professor, Department of Pharmacy, University of Tennessee College of Pharmacy, Memphis, Tennessee. Address correspondence to: Robert B. Parker, PharmD, Associate Professor, Department of Pharmacy, University of Tennessee College of Pharmacy, 26 South Dunlap Street, Memphis, TN rparker@utmem.edu. no measurable increase in these biomarkers are thought to have UA; any increase in cardiac biomarkers is NSTE- MI. These markers are detectable in the bloodstream for hours after the onset of ischemic chest pain. The presence of these biomarkers is often the only finding that enables the clinician to distinguish UA (no detectable biomarkers) from NSTEMI (increased biomarkers). Unstable angina/non ST-segment elevation myocardial infarction is associated with an increased risk of cardiac death and MI. With heart disease as the number one cause of death in the United States and UA/NSTEMI a very common manifestation of this disease, it is not surprising that UA/NSTEMI is a major cause of emergency medical care and hospitalizations. The prevalence of UA/NSTEMI is increasing; one study found that the prevalence of non Q-wave infarctions increased from 45% in 1994 to 63% in 1999 (P =.0001). 1 Therefore, UA/NSTE- MI may also be encountered in outpatient/non-emergency department settings. Of those patients who experience a fatal MI, more than 50% will die within the first hour without receiving medical attention. 2 In 2002, the American Heart Association (AHA) and the American College of Cardiology (ACC) updated their guidelines on the management of patients with UA/NSTEMI. 3 The updated guidelines recommend stratifying the patient by risk of death or nonfatal MI and the likelihood that the presenting symptoms are caused by ACS secondary to coronary artery disease. Stratification is based on the patient s history, physical examination, character of chest pain, ECG findings, and cardiac biomarkers. Once a patient is documented as being high risk, the patient should be hospitalized and standard medical therapy initiated. The recommendations on hospitalization for lowerrisk patients are outlined in detail in the guideline. 3 Patients who have acute ischemia (ie, recurrent ischemia and ST-segment shift, deep T-wave inversion, Advanced Studies in Pharmacy 7
2 or positive cardiac markers) should begin receiving the appropriate anti-ischemic therapies: aspirin, β blockers, nitrates, antithrombin regimen, and glycoprotein (GP) IIb/IIIa receptor antagonist/inhibitors, along with proper monitoring. These patients are thought to be medically managed. During this time, the clinician will determine if the patient will continue with an early conservative strategy (ie, evaluation of left ventricular function and possibly a stress test) or an early invasive strategy (the angiographic strategy) involving a percutaneous coronary intervention (PCI) possibly or coronary artery bypass surgery. PCI refers to a family of percutaneous techniques that often involves balloon angioplasty and intracoronary stenting. THE COAGULATION CASCADE In ACS, the coagulation cascade is typically activated by exposure of tissue factor after rupture of an atherosclerotic plaque. Tissue factor, in combination with factor VIIa, activates factor X to Xa, which leads to thrombin formation, fibrin deposition, platelet activation, and development of a clot in the coronary artery. This activation of the coagulation cascade serves as the basis for the use of anticoagulant drugs in the pharmacotherapy of ACS (Figure 1). 4 Unfractionated heparin consists of oligosaccharide chains of varying length; it is not a molecularly consistent product, thus dosing is in units of activity rather than in weight. UFH is delivered by continuous intravenous infusion, initiated with a bolus injection. Its activity and therapeutic levels should be monitored every 6 hours through the activated partial thromboplastin time, a measure of the time to clot formation. Unfractionated heparin has a short half-life, ranging from 1 to 5 hours, depending on the dose administered. Because of this relatively short halflife, the drug is quickly cleared from the plasma. Thus, if severe bleeding occurs, the anticoagulant effect of UFH does not persist for long periods after Figure 1. Schematic of the Coagulation Cascade and the Targets of UFH and LMWH THERAPEUTIC OPTIONS The 2 anticoagulant therapies available are unfractionated heparin (UFH) and low-molecular weight heparin (LMWH). Heparin is a glycosaminoglycan found in mast cells. It consists of a core protein attached to several long polysaccharide chains of varying length. During its synthesis in the cell, the polysaccharide units undergo a series of modifications, including N-deacetylation, N- and O-sulfation, and epimerization. There is no set pattern to these modifications, thus the oligosaccharide chains vary widely. However, there is a pentasaccharide sequence that is known to be the active site of heparin in anticoagulation (Figure 2); it occurs in approximately 30% of heparin molecules. 5 Heparin s anticoagulant activity is mediated by binding to antithrombin III, accelerating the effect of antithrombin III on thrombin by at least 1000-fold. As shown in Figure 1, antithrombin inhibits factor Xa and thrombin, thus preventing coagulation. In acute coronary syndromes, thrombosis is typically initiated through exposure of tissue factor at the site of a disrupted plaque. In the coagulation cascade, unfractionated heparin and low-molecular weight heparin act by complexing with antithrombin III. LMWH = low-molecular weight heparin; UFH = unfractionated heparin. Reproduced with permission from Wong et al. JAMA. 2003;289: November 2004
3 discontinuation of the infusion. In addition, its anticoagulant effect can be completely reversed by protamine, which is often done after cardiac surgery or other vascular procedures. Therefore, cardiologists Figure 2. Antithrombin-Binding Pentasaccharide of Heparin Reproduced with permission from Majerus et al. Anticoagulant, thrombolytic, and antiplatelet drugs. In: Hardman JG, Limbird LE, eds. Goodman & Gilman s The Pharmacological Basis of Therapeutics. 9th ed. New York, NY: McGraw-Hill; 1996: have traditionally had a greater comfort level with UFH because its anticoagulant effect can be readily monitored and reversed. However, UFH also has several limitations that are important to consider, especially with the LMWHs that are available. Table 1 summarizes the limitations of UFH and their pharmacologic and clinical consequences, in addition to the potential pharmacologic advantages of LMWH. 4 Those limitations include a narrow therapeutic window, poorly predictable kinetics, risk of platelet activation/thrombocytopenia, and inability to inhibit clot-bound thrombin. As the name suggests, LMWHs consist of shorter heparin chains. They also inhibit clot formation by their effects on factor Xa and antithrombin III; however, the polysaccharide chains that are of Table 1. Limitations of Unfractionated Heparin Unfractionated Heparin Potential Pharmacologic Advantage Properties Pharmacologic Consequences Clinical Consequences of LMWH over UFH Thrombin-dependent properties Nonspecific protein binding Less drug binding to thrombin; Variable level of anticoagulation Less nonspecific protein binding sensitivity to inactivation by requiring monitoring of activated platelet factor 4 and histidine- PTT rich glycoprotein Short plasma half-life Poor bioavailability with a single Requires continuous IV infusion Long plasma half-life relative to UFH IV or SC dose enables intermittent IV or SC injections without concomitant infusions Relative inability to inhibit Increased thrombin generation Rebound thrombosis during and Decreased new thrombin generation clot-bound thrombin after clot lysis in presence of after UFH treatment because of superior proximal Xa therapeutic levels of UFH inhibition Depletion of TFPI Decreased attenuation of tissue Rebound hypercoagulability Relatively less TFPI depletion factor/factor VIIa complex Thrombin-independent properties Increased binding to platelets Increased immunogenicity; Increased potential for bleeding, Relatively less platelet activation and increased platelet activation HITTS, or thrombosis platelet-endothelial interactions and adhesion to endothelium Inability to blunt increase of Elevations of vwf in ACS Increased potential for thrombosis Superior attenuation of the increase vwf in ACS in vwf in ACS ACS = acute coronary syndrome; HITTS = heparin-induced thrombocytopenia and thrombosis syndrome; IV = intravenous; LMWH = low-molecular weight heparin; PTT = partial thromboplastin time; SC = subcutaneous; TFPI = tissue factor pathway inhibitor; UFH = unfractionated heparin; vwf = von Willebrand factor. Adapted with permission from Wong et al. JAMA. 2003;289: Advanced Studies in Pharmacy 9
4 insufficient length to activate antithrombin III exert most of their effect through factor Xa. 5 There are 2 LMWH preparations available in the United States: enoxaparin and dalteparin. However, enoxaparin has a larger amount of data to support its use and appears to be more effective compared to dalteparin in UA, although direct head-to-head studies have not yet been performed (Figure 3). 3,6-9 Enoxaparin is named in the ACC/AHA guidelines as an equivalent option to UFH. It is also considered to be possibly preferable to UFH based on class IIa evidence (Table 2). 3 Enoxaparin is administered in a fixed or weightadjusted dosage once or twice daily through subcutaneous injection. The limitations associated with enoxaparin revolve primarily around dosing. In those patients with renal insufficiency, dosing adjustments are required, and optimal dosing during invasive cardiac procedures has not been prospectively defined. However, these limitations can be solved with experience. It has a longer halflife ( hours, depending on dosing and renal function) than UFH, thus its antithrombotic effect may persist much longer than UFH. Also, enoxaparin's anticoagulant effect can only be partially reversed with protamine. Antiplatelet therapy (aspirin, ticlopidine, or clopidogrel) and GP IIb/IIIa inhibitors are also recommended in the guideline for immediate administration (Table 3). 3 The GP IIb/IIIa receptor is found on platelets and is involved in binding to fibrinogen and other ligands upon activation. GP IIb/IIIa antagonists bind to the receptor and prevent fibrinogen binding. Their role in ACS management has been evolving since the 2002 guidelines were published, in part because enoxaparin is used more frequently in these patients. The current guideline recommends an early invasive strategy (ie, PCI) in patients with UA/NSTEMI without serious comorbidity and who have any of the listed high-risk indicators. 3 Since the guideline was published, management of ACS has continued to support earlier and more aggressive interventions and increased use of GP IIb/IIIa inhibitors. The benefits of enoxaparin compared to UFH are well documented in patients with UA/NSTEMI undergoing medical therapy. However, many patients with UA/NSTEMI are now managed with an early invasive strategy that often includes PCI. Compared to UFH, there is lit- Figure 3. Low-Molecular Weight Heparin in Unstable Angina: Effects on Triple Endpoints Nadroparin is currently only available in Canada. Reprinted with permission from Braunwald et al. ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-st-segment elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Patients with Unstable Angina). Available at: Accessed October 1, Table 2. Recommendations for Heparin Use for Unstable Angina/Non ST-Segment Elevation Myocardial Infarction Class I Anticoagulation with subcutaneous LMWH or intravenous UFH should be added to antiplatelet therapy with ASA and/or clopidogrel. Level of evidence: A Class IIa Enoxaparin is preferable to UFH as an anticoagulant in patients with UA/NSTEMI, in the absence of renal failure and unless CABG is planned within 24 hours. Level of evidence: A ASA = acetylsalicylic acid; CABG = coronary artery bypass grafting; LMWH = lowmolecular weight heparin; NSTEMI = non ST-segment elevation myocardial infarction; UA = unstable angina; UFH = unfractionated heparin. Adapted with permission from Braunwald et al. ACC/AHA 2002 guideline update for the management of patients with unstable angina and non ST-segment elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Patients with Unstable Angina). Available at: Accessed October 1, Table 3. Class I Recommendations for Antithrombotic Therapy Definite ACS with Continuing Ischemia or Other High-Risk Possible ACS Likely/Definite ACS Features or Planned Intervention Aspirin Aspirin + SC LMWH Aspirin + IV heparin + IV or IV heparin platelet GP IIb/IIIa inhibitor ACS = acute coronary syndrome; GP = glycoprotein; IV = intravenous; LMWH = lowmolecular weight heparin; SC = subcutaneous. Adapted with permission from Braunwald et al. ACC/AHA 2002 guideline update for the management of patients with unstable angina and non ST-segment elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Patients with Unstable Angina). Available at: Accessed October 1, November 2004
5 tle information on the safety and efficacy of enoxaparin use in patients undergoing early invasive management. Therefore, it is imperative to evaluate enoxaparin in this setting. The SYNERGY (Superior Yield of the New Strategy of Enoxaparin, Revascularization, and Glycoprotein IIb/IIIa Inhibitors) study has recently been published. 10 It was designed to assess the safety and efficacy of enoxaparin in high-risk patients with ACS managed with an early invasive strategy. This issue of Advanced Studies in Pharmacy provides a reprint of that study and important information regarding the study rationale, design, and clinical implications by one of the study s Executive Committee members, Dr Marc Cohen. Dr Cohen has been an investigator in several clinical studies of UFH and enoxaparin; he explains some of the clinical trial history with the heparins that led to the SYNERGY study, and discusses the study s strengths and weaknesses. Dr Sarah Spinler, a clinical pharmacist with extensive experience in cardiology and the clinical trials of UFH and enoxaparin in UA/NSTEMI, offers her insights into the SYNERGY results and how they will affect clinical pharmacy practice. She provides practical commentary on the issues faced by pharmacists in managing patients with ACS. As pharmacists continue to work to optimize the pharmacotherapy of patients with ACS, it is important that we keep abreast of issues surrounding use of anticoagulant and other therapies used in the treatment of these patients. REFERENCES 1. Rogers WJ, Canto JG, Lambrew CT, et al. Temporal trends in the treatment of over 1.5 million patients with myocardial infarction in the US from 1990 through 1999: the National Registry of Myocardial Infarction 1, 2, and 3. J Am Coll Cardiol. 2000;36: Ryan TJ, Anderson JL, Antman EM, et al. ACC/AHA guidelines for the management of patients with acute myocardial infarction. J Am Coll Cardiol. 1996;28: Braunwald E, Antman EM, Beasley JW, et al. ACC/AHA 2002 guideline update for the management of patients with unstable angina and non ST-segment elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Patients with Unstable Angina). Available at: unstable/unstable.pdf. Accessed October 1, Wong GC, Giugliano RP, Antman EM. Use of low-molecular-weight heparins in the management of acute coronary artery syndromes and percutaneous coronary intervention. JAMA. 2003;289: Majerus PW, Broze GJ Jr, Miletich JP, Tollefsen DM. Anticoagulant, thrombolytic, and antiplatelet drugs. In: Hardman JG, Limbird LE, eds. Goodman & Gilman s The Pharmacological Basis of Therapeutics. 9th ed. New York, NY: McGraw-Hill; 1996: Klein W, Buchwald A, Hillis SE, et al. Comparison of lowmolecular-weight heparin with unfractionated heparin acutely and with placebo for 6 weeks in the management of unstable coronary artery disease. Fragmin in unstable coronary artery disease study (FRIC) [published correction appears in Circulation. 1998;97:413]. Circulation. 1997;96: Comparison of two treatment durations (6 days and 14 days) of a low molecular weight heparin with a 6-day treatment of unfractionated heparin in the initial management of unstable angina or non-q-wave myocardial infarction: FRAX.I.S. (FRAxiparine in Ischaemic Syndrome). Eur Heart J. 1999;20: Cohen M, Demers C, Gurfinkel EP, et al. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group. N Engl J Med. 1997;337: Antman EM, McCabe CH, Gurfinkel EP, et al. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-q-wave myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) 11B trial. Circulation. 1999;100: Ferguson JJ, Califf RM, Antman EM, et al. Enoxaparin vs unfractionated heparin in high-risk patients with non-st-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYN- ERGY randomized trial. JAMA. 2004;292: Advanced Studies in Pharmacy 11
Anticoagulation therapy in acute coronary syndromes according to current guidelines
Acute management of ACS Anticoagulation therapy in acute coronary syndromes according to current guidelines Marcin Grabowski, Marcin Leszczyk, Andrzej Cacko, Krzysztof J. Filipiak, Grzegorz Opolski 1 st
More informationCHAPTER 17 Antithrombotic Agents Heparins
CHAPTER 17 Antithrombotic Agents Heparins Structure Mechanism of Action Pharmacokinetics Limitations of Unfractionated Heparin Heparin Induced Thrombocytopenia Heparin Rebound Low Molecular Weight Heparins
More informationUpdate on Antithrombotic Therapy in Acute Coronary Syndrome
Update on Antithrombotic Therapy in Acute Coronary Syndrome Laura Tsang November 13, 2006 Objectives: By the end of this session, you should understand: The role of antithrombotics in ACS Their mechanisms
More informationQUT Digital Repository:
QUT Digital Repository: http://eprints.qut.edu.au/ This is the author s version of this journal article. Published as: Doggrell, Sheila (2010) New drugs for the treatment of coronary artery syndromes.
More informationCLINICIAN INTERVIEW RECOGNIZING ACS AND STRATIFYING RISK IN PRIMARY CARE. An interview with A. Michael Lincoff, MD, and Eric R. Bates, MD, FACC, FAHA
RECOGNIZING ACS AND STRATIFYING RISK IN PRIMARY CARE An interview with A. Michael Lincoff, MD, and Eric R. Bates, MD, FACC, FAHA Dr Lincoff is an interventional cardiologist and the Vice Chairman for Research
More informationCangrelor: Is it the new CHAMPION for PCI? Robert Barcelona, PharmD, BCPS Clinical Pharmacy Specialist, Cardiac Intensive Care Unit November 13, 2015
Cangrelor: Is it the new CHAMPION for PCI? Robert Barcelona, PharmD, BCPS Clinical Pharmacy Specialist, Cardiac Intensive Care Unit November 13, 2015 Objectives Review the pharmacology and pharmacokinetic
More informationNOVEL ANTI-THROMBOTIC THERAPIES FOR ACUTE CORONARY SYNDROME: DIRECT THROMBIN INHIBITORS
Judd E. Hollander, MD Professor, Clinical Research Director, Department of Emergency Medicine University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania OBJECTIVES: 1. Discuss the concept
More informationAcute Coronary Syndromes
Overview Acute Coronary Syndromes Rabeea Aboufakher, MD, FACC, FSCAI Section Chief of Cardiology Altru Health System Grand Forks, ND Epidemiology Pathophysiology Clinical features and diagnosis STEMI management
More informationAcute coronary syndrome (ACS) is a potentially
DIAGNOSING ACUTE CORONARY SYNDROME AND DETERMINING PATIENT RISK Edith A. Nutescu, PharmD* ABSTRACT Acute coronary syndrome is a form of coronary artery disease and has a broad range of clinical presentations.
More informationST-segment Elevation Myocardial Infarction (STEMI): Optimal Antiplatelet and Anti-thrombotic Therapy in the Emergency Department
ST-segment Elevation Myocardial Infarction (STEMI): Optimal Antiplatelet and Anti-thrombotic Therapy in the Emergency Department decision-making. They have become the cornerstone of many ED protocols for
More informationContinuing Medical Education Post-Test
Continuing Medical Education Post-Test Based on the information presented in this monograph, please choose one correct response for each of the following questions or statements. Record your answers on
More informationLearning Objectives. Epidemiology of Acute Coronary Syndrome
Cardiovascular Update: Antiplatelet therapy in acute coronary syndromes PHILLIP WEEKS, PHARM.D., BCPS-AQ CARDIOLOGY Learning Objectives Interpret guidelines as they relate to constructing an antiplatelet
More informationFastTest. You ve read the book now test yourself
FastTest You ve read the book...... now test yourself To ensure you have learned the key points that will improve your patient care, read the authors questions below. The answers will refer you back to
More informationOtamixaban for non-st-segment elevation acute coronary syndrome
Otamixaban for non-st-segment elevation acute coronary syndrome September 2011 This technology summary is based on information available at the time of research and a limited literature search. It is not
More informationHeart disease is the leading cause of death
ACS AND ANTIPLATELET MANAGEMENT: UPDATED GUIDELINES AND CURRENT TRIALS Christopher P. Cannon, MD,* ABSTRACT Acute coronary syndrome (ACS) is an important cause of morbidity and mortality in the US population
More informationAcute Myocardial Infarction. Willis E. Godin D.O., FACC
Acute Myocardial Infarction Willis E. Godin D.O., FACC Acute Myocardial Infarction Definition: Decreased delivery of oxygen and nutrients to the myocardium Myocardial tissue necrosis causing irreparable
More informationProspective Comparison of Hemorrhagic Complications After Treatment With Enoxaparin
Prospective Comparison of Hemorrhagic Complications After Treatment With Versus Unfractionated Heparin for Unstable Angina Pectoris or Non ST-Segment Elevation Acute Myocardial Infarction Scott D. Berkowitz,
More informationAn update on the management of UA / NSTEMI. Michael H. Crawford, MD
An update on the management of UA / NSTEMI Michael H. Crawford, MD New ACC/AHA Guidelines 2007 What s s new in the last 5 years CT imaging advances Ascendancy of troponin and BNP Clarification of ACEI/ARB
More informationAcute coronary syndromes
Acute coronary syndromes 1 Acute coronary syndromes Acute coronary syndromes results primarily from diminished myocardial blood flow secondary to an occlusive or partially occlusive coronary artery thrombus.
More informationAcute Myocardial Infarction
Acute Myocardial Infarction Hafeza Shaikh, DO, FACC, RPVI Lourdes Cardiology Services Asst.Program Director, Cardiology Fellowship Associate Professor, ROWAN-SOM Acute Myocardial Infarction Definition:
More informationRole of Clopidogrel in Acute Coronary Syndromes. Hossam Kandil,, MD. Professor of Cardiology Cairo University
Role of Clopidogrel in Acute Coronary Syndromes Hossam Kandil,, MD Professor of Cardiology Cairo University ACS Treatment Strategies Reperfusion/Revascularization Therapy Thrombolysis PCI (with/ without
More informationDirect Thrombin Inhibitors for PCI Pharmacology: Role of Bivalirudin in High-Risk PCI
Direct Thrombin Inhibitors for PCI Pharmacology: Role of Bivalirudin in High-Risk PCI Charles A. Simonton MD, FACC, FSCAI Sanger Clinic Medical Director Clinical Innovation and Research Carolinas Heart
More information2007 ACC/AHA GUIDELINES FOR THE MANAGEMENT OF NSTE-ACS: OPTIMAL ANTICOAGULATION AND ANTIPLATELET THERAPY
2007 ACC/AHA GUIDELINES FOR THE MANAGEMENT OF NSTE-ACS: OPTIMAL ANTICOAGULATION AND ANTIPLATELET THERAPY Charles V. Pollack, Jr., MA, MD, FACEP, FAAEM, FAHA Professor and Chairman, Department of Emergency
More informationJournal of the American College of Cardiology Vol. 35, No. 7, by the American College of Cardiology ISSN /00/$20.
Journal of the American College of Cardiology Vol. 35, No. 7, 2000 2000 by the American College of Cardiology ISSN 0735-1097/00/$20.00 Published by Elsevier Science Inc. PII S0735-1097(00)00684-3 REVIEW
More informationObjectives. Acute Coronary Syndromes; The Nuts and Bolts. Overview. Quick quiz.. How dose the plaque start?
Objectives Acute Coronary Syndromes; The Nuts and Bolts Michael P. Gulseth, Pharm. D., BCPS Pharmacotherapy II Spring 2006 Compare and contrast pathophysiology of unstable angina (UA), non-st segment elevation
More informationThe Role of Low-Molecular-Weight Heparin in the Management of Acute Coronary Syndromes
Journal of the American College of Cardiology Vol. 41, No. 4 Suppl S 2003 by the American College of Cardiology Foundation ISSN 0735-1097/03/$30.00 Published by Elsevier Science Inc. doi:10.1016/s0735-1097(02)02901-7
More informationAppendix: ACC/AHA and ESC practice guidelines
Appendix: ACC/AHA and ESC practice guidelines Definitions for guideline recommendations and level of evidence Recommendation Class I Class IIa Class IIb Class III Level of evidence Level A Level B Level
More informationREVIEW EPIDEMIOLOGY 236
ACUTE CORONARY SYNDROME: THE COMMUNITY PHARMACISTS ROLE IN THE CONTINUUM OF CARE William E. Dager, PharmD * ABSTRACT Acute coronary syndrome describes a broad range of symptoms caused by myocardial ischemia
More informationTiming of Anti-Platelet Therapy for ACS (EARLY-ACS & ACUITY) Mitchell W. Krucoff, MD, FACC
Timing of Anti-Platelet Therapy for ACS (EARLY-ACS & ACUITY) Mitchell W. Krucoff, MD, FACC Professor, Medicine/Cardiology Duke University Medical Center Director, Cardiovascular Devices Unit Duke Clinical
More informationGuidelines and Performance Measures for the Management of Acute Coronary Syndrome
Guidelines and Performance Measures for the Management of Acute Coronary Syndrome Piotr Sobieszczyk, MD ABSTRACT BACKGROUND: Acute coronary syndrome (ACS) is caused by reduced perfusion of the myocardium
More informationFACTOR Xa AND PAR-1 BLOCKER : ATLAS-2, APPRAISE-2 & TRACER TRIALS
New Horizons In Atherothrombosis Treatment 2012 순환기춘계학술대회 FACTOR Xa AND PAR-1 BLOCKER : ATLAS-2, APPRAISE-2 & TRACER TRIALS Division of Cardiology, Jeonbuk National University Medical School Jei Keon Chae,
More informationCHAPTER-I MYOCARDIAL INFARCTION
CHAPTER-I MYOCARDIAL INFARCTION Definition A myocardial infarction, more commonly known as MI or acute myocardial infarction (AMI) or heart attack is a condition where there is interruption of blood supply
More informationThe PAIN Pathway for the Management of Acute Coronary Syndrome
2 The PAIN Pathway for the Management of Acute Coronary Syndrome Eyal Herzog, Emad Aziz, and Mun K. Hong Acute coronary syndrome (ACS) subsumes a spectrum of clinical entities, ranging from unstable angina
More informationAcute coronary syndromes (ACS), including unstable
n report n Acute Coronary Syndromes: Morbidity, Mortality, and Pharmacoeconomic Burden Daniel M. Kolansky, MD Abstract Acute coronary syndromes (ACS), which include unstable angina and myocardial infarction
More informationPrehospital and Hospital Care of Acute Coronary Syndrome
Ischemic Heart Diseases Prehospital and Hospital Care of Acute Coronary Syndrome JMAJ 46(8): 339 346, 2003 Katsuo KANMATSUSE* and Ikuyoshi WATANABE** * Professor, Second Internal Medicine, Nihon University,
More informationAcute Coronary Syndromes. January 9, 2013 Chris Chiles M.D. FACC
Acute Coronary Syndromes January 9, 2013 Chris Chiles M.D. FACC Disclosures None- not even a breakfast burrito from a drug company Hospitalizations in the U.S. Due to ACS Acute Coronary Syndromes* 1.57
More informationThe restoration of coronary flow after an
Pharmacological Reperfusion in Acute Myicardial Infarction after ASSENT 3 and GUSTO V [81] DANIEL FERREIRA, MD, FESC Serviço de Cardiologia, Hospital Fernando Fonseca, Amadora, Portugal Rev Port Cardiol
More informationREVIEW DIAGNOSING ACUTE CORONARY SYNDROME AND DETERMINING PATIENT RISK. Edith A. Nutescu, PharmD * ABSTRACT INTRODUCTION
DIAGNOSING ACUTE CORONARY SYNDROME AND DETERMINING PATIENT RISK Edith A. Nutescu, PharmD * ABSTRACT Acute coronary syndrome is a form of coronary artery disease, which has a broad range of clinical presentations.
More informationFissuring of atherosclerotic plaque triggers thrombus formation and is the
New advances in the management of acute coronary syndromes: 4. Low-molecular-weight heparins Walter Ageno, * Alexander G.G. Turpie The case Mr. K, a 57-year-old man, presents to the emergency department
More informationCase Study 50 YEAR OLD MALE WITH UNSTABLE ANGINA
Case Study 50 YEAR OLD MALE WITH UNSTABLE ANGINA Case History A 50-year-old man with type 1 diabetes mellitus and hypertension presents after experiencing 1 hour of midsternal chest pain that began after
More informationContinuing Medical Education Post-Test
Continuing Medical Education Post-Test Based on the information presented in this monograph, please choose one correct response for each of the following questions or statements. Record your answers on
More informationPatient characteristics Intervention Comparison Length of followup
ANTICOAGULANT CHAPTER Low Molecular Weight Heparins compared with Unfractionated Heparin Ref ID: 1903 Reference Antman EM, McCabe CH, Gurfinkel EP et al. Enoxaparin prevents death and cardiac ischemic
More informationAcute Coronary syndrome
Acute Coronary syndrome 7th Annual Pharmacotherapy Conference ACS Pathophysiology rupture or erosion of a vulnerable, lipidladen, atherosclerotic coronary plaque, resulting in exposure of circulating blood
More informationDIFFERENTIATING THE PATIENT WITH UNDIFFERENTIATED CHEST PAIN
DIFFERENTIATING THE PATIENT WITH UNDIFFERENTIATED CHEST PAIN Objectives Gain competence in evaluating chest pain Recognize features of moderate risk unstable angina Review initial management of UA and
More informationClopidogrel and ASA after CABG for NSTEMI
Clopidogrel and ASA after CABG for NSTEMI May 17, 2007 Justin Lee Pharmacy Resident University Health Network Objectives At the end of this session, you should be able to: Explain the rationale for antiplatelet
More informationAcute Coronary Syndrome. ACC/AHA 2002 Guidelines
Acute Coronary Syndrome ACC/AHA 2002 Guidelines ACS Unstable Angina Non ST elevation MI ST elevation MI ACS UA and Non STEMI described in these guidelines Management of STEMI described in separate guidelines
More informationAcute Coronary Syndrome. Cindy Baker, MD FACC Director Peripheral Vascular Interventions Division of Cardiovascular Medicine
Acute Coronary Syndrome Cindy Baker, MD FACC Director Peripheral Vascular Interventions Division of Cardiovascular Medicine Topics Timing is everything So many drugs to choose from What s a MINOCA? 2 Acute
More informationAcute Coronary Syndrome. Sonny Achtchi, DO
Acute Coronary Syndrome Sonny Achtchi, DO Objectives Understand evidence based and practice based treatments for stabilization and initial management of ACS Become familiar with ACS risk stratification
More informationTitle: Low Molecular Weight Heparins (LMWH), fondaparinux (Arixtra)
Origination: 03/29/05 Revised: 09/01/10 Annual Review: 11/20/13 Purpose: To provide guidelines and criteria for the review and decision determination of requests for medications that requires prior authorization.
More informationBelinda Green, Cardiologist, SDHB, 2016
Acute Coronary syndromes All STEMI ALL Non STEMI Unstable angina Belinda Green, Cardiologist, SDHB, 2016 Thrombus in proximal LAD Underlying pathophysiology Be very afraid for your patient Wellens
More informationTIMI, PURSUIT, and GRACE risk scores: sustained prognostic value and interaction with revascularization in NSTE-ACS
European Heart Journal (2005) 26, 865 872 doi:10.1093/eurheartj/ehi187 Clinical research TIMI, PURSUIT, and GRACE risk scores: sustained prognostic value and interaction with revascularization in NSTE-ACS
More informationAcute Coronary Syndromes: Selective vs Early Invasive Strategies
Acute Coronary Syndromes: Selective vs Early Invasive Strategies WilliamE.Boden,MD,FACCandVipulGupta,MBBS,MPH Division of Cardiovascular Medicine, University at Buffalo Schools of Medicine and Public Health,
More informationS PECIAL A RTICLE. Combination Antiplatelet Therapy: Implications for Pharmacists
S PECIAL A RTICLE Combination Antiplatelet Therapy: Implications for Pharmacists Robert L. Talbert, Pharm.D., FCCP, Sarah A. Spinler, Pharm.D., FCCP, Jean M. Nappi, Pharm.D., FCCP, and Michael B. Bottorff,
More informationMeasuring Natriuretic Peptides in Acute Coronary Syndromes
Measuring Natriuretic Peptides in Acute Coronary Syndromes Peter A. McCullough, MD, MPH, FACC, FACP, FAHA, FCCP Consultant Cardiologist Chief Academic and Scientific Officer St. John Providence Health
More informationColumbia University Medical Center Cardiovascular Research Foundation
STEMI and NSTEMI Pharmacology Confusion: How to Choose and Use Antithrombins (Unfractionated and Low Molecular Heparins, Bivalirudin, Fondaparinux) and Antiplatelet Agents (Aspirin, Clopidogrel and Prasugrel)
More informationACS: What happens after the acute phase? Frans Van de Werf, MD, PhD Leuven, Belgium
ACS: What happens after the acute phase? Frans Van de Werf, MD, PhD Leuven, Belgium 4/14/2011 Cumulative death rates in 3721 ACS patients from UK and Belgium at ± 5 year (GRACE) 25 20 15 19% TOTAL 14%
More informationClinical Case. Management of ACS Based on ACC/AHA & ESC Guidelines. Clinical Case 4/22/12. UA/NSTEMI: Definition
Clinical Case Management of ACS Based on ACC/AHA & ESC Guidelines Dr Badri Paudel Mr M 75M Poorly controlled diabetic Smoker Presented on Sat 7pm Intense burning in the retrosternal area Clinical Case
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 21 July 2010
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 21 July 2010 DUOPLAVIN 75 mg/75 mg, film-coated tablet B/30 (CIP code: 359 022-6) B/30 (CIP code: 382 063-7) DUOPLAVIN
More informationNova Scotia Guidelines for Acute Coronary Syndromes (Updating the 2008 Antiplatelet Section of the Guidelines)
Cardiovascular Health Nova Scotia Guideline Update Nova Scotia Guidelines for Acute Coronary Syndromes (Updating the 2008 Antiplatelet Section of the Guidelines) Authors: Dr. M. Love, Dr. I. Bata, K. Harrigan
More informationWhich drug do you prefer for stable CAD? - P2Y12 inhibitor
Which drug do you prefer for stable CAD? - P2Y12 inhibitor Jung Rae Cho, MD, PhD Cardiovascular Division, Department of Internal Medicine Kangnam Sacred Heart Hospital, Hallym University Medical Center,
More information2003 by the American College of Cardiology Foundation ISSN /03/$30.00
Journal of the American College of Cardiology Vol. 41, No. 4 Suppl S 2003 by the American College of Cardiology Foundation ISSN 0735-1097/03/$30.00 Published by Elsevier Science Inc. doi:10.1016/s0735-1097(02)02963-7
More informationOpinion 15 May ARIXTRA 2.5 mg/0.5 ml, solution for injection in pre-filled syringe B/10 (CIP: )
The legally binding text is the original French version TRANSPARENCY COMMITTEE Opinion 15 May 2013 ARIXTRA 2.5 mg/0.5 ml, solution for injection in pre-filled syringe B/10 (CIP: 34009 563 619 7 7) Applicant:
More informationThe Thrombolysis In Myocardial Infarction Risk Score in Unstable Angina/ Non ST-Segment Elevation Myocardial Infarction
Journal of the American College of Cardiology Vol. 41, No. 4 Suppl S 2003 by the American College of Cardiology Foundation ISSN 0735-1097/03/$30.00 Published by Elsevier Science Inc. doi:10.1016/s0735-1097(02)03019-x
More informationTHE INCITING EVENT IN AN ACUTE
CLINICAL CARDIOLOGY Use of Low-Molecular-Weight Heparins in the Management of Acute Coronary Artery Syndromes and Percutaneous Coronary Intervention Graham C. Wong, MD Robert P. Giugliano, MD, SM Elliott
More informationA Multicenter Randomized Trial of Immediate Versus Delayed Invasive Strategy in Patients with Non-ST Elevation ACS
Angioplasty to Blunt the rise Of troponin in Acute coronary syndromes Randomized for an immediate or Delayed intervention A Multicenter Randomized Trial of Immediate Versus Delayed Invasive Strategy in
More information2003 by the American College of Cardiology Foundation ISSN /03/$30.00
Journal of the American College of Cardiology Vol. 41, No. 4 Suppl S 2003 by the American College of Cardiology Foundation ISSN 0735-1097/03/$30.00 Published by Elsevier Science Inc. PII S0735-1097(02)02688-8
More informationAwealth of research in acute coronary syndrome
CLINICAL TRIAL SUPPORT OF THE USE OF CRITICAL PATHWAYS IN IMPROVING PATIENT OUTCOMES Judy W. M. Cheng, PharmD, MPH, BCPS, FCCP * ABSTRACT Acute coronary syndrome (ACS) is a common condition encountered
More informationNew Guidelines for Evaluating Acute Coronary Syndrome
New Guidelines for Evaluating Acute Coronary Syndrome The American College of Cardiology and the American Heart Association [Clinician Reviews 11(1):73-86, 2001. 2001 Clinicians Publishing Group] Introduction
More informationHorizon Scanning Centre November 2012
Horizon Scanning Centre November 2012 Cangrelor to reduce platelet aggregation and thrombosis in patients undergoing percutaneous coronary intervention99 SUMMARY NIHR HSC ID: 2424 This briefing is based
More informationST Elevation Myocardial Infarction
ST Elevation Myocardial Infarction Scott M. Lilly, MD, PhD Assistant Professor Clinical Department of Cardiovascular Medicine The Ohio State University Wexner Medical Center Case Presentation 46 year old
More informationLow molecular weight heparins. Current Status BR BANSODE. 74 Medicine Update
74 Medicine Update 14 Low Molecular Weight Heparin Current Status BR BANSODE McLean, 90 years ago, discovered that heparin has antithrombotic properties. Brinkhous and associates demonstrated that heparin
More informationMedicine Dr. Omed Lecture 2 Stable and Unstable Angina
Medicine Dr. Omed Lecture 2 Stable and Unstable Angina Risk stratification in stable angina. High Risk; *post infarct angina, *poor effort tolerance, *ischemia at low workload, *left main or three vessel
More informationOptimal antiplatelet and anticoagulant therapy for patients treated in STEMI network
Torino 6 Joint meeting with Mayo Clinic Great Innovation in Cardiology 14-15 Ottobre 2010 Optimal antiplatelet and anticoagulant therapy for patients treated in STEMI network Diego Ardissino Ischemic vs
More informationPercutaneous Coronary Intervention After Subcutaneous Enoxaparin Pretreatment in Patients With Unstable Angina Pectoris
Percutaneous Coronary Intervention After Subcutaneous Enoxaparin Pretreatment in Patients With Unstable Angina Pectoris J.Ph. Collet, MD, PhD; G. Montalescot, MD, PhD; L. Lison, MD; R. Choussat, MD; A.
More informationMyocardial Infarction In Dr.Yahya Kiwan
Myocardial Infarction In 2007 Dr.Yahya Kiwan New Definition Of Acute Myocardial Infarction The term of myocardial infarction should be used when there is evidence of myocardial necrosis in a clinical setting
More informationWhen the learner has completed this module, she/he will be able to:
Thrombolytics and Myocardial Infarction WWW.RN.ORG Reviewed September 2017, Expires September 2019 Provider Information and Specifics available on our Website Unauthorized Distribution Prohibited 2017
More informationNew Antithrombotic and Antiplatelet Drugs in CAD : (Factor Xa inhibitors, Direct Thrombin inhibitors and Prasugrel)
New Antithrombotic and Antiplatelet Drugs in CAD : (Factor Xa inhibitors, Direct Thrombin inhibitors and Prasugrel) Limitations and Advantages of UFH and LMWH Biological limitations of UFH : 1. immune-mediated
More informationST Elevation Myocardial Infarction
ST Elevation Myocardial Infarction Scott M. Lilly, MD, PhD Assistant Professor Clinical Department of Cardiovascular Medicine The Ohio State University Wexner Medical Center Outline Case Presentation STEMI
More informationΔιάρκεια διπλής αντιαιμοπεταλιακής αγωγής. Νικόλαος Γ.Πατσουράκος Καρδιολόγος, Επιμελητής Α ΕΣΥ Τζάνειο Γενικό Νοσοκομείο Πειραιά
Διάρκεια διπλής αντιαιμοπεταλιακής αγωγής Νικόλαος Γ.Πατσουράκος Καρδιολόγος, Επιμελητής Α ΕΣΥ Τζάνειο Γενικό Νοσοκομείο Πειραιά International ACS guidelines: Recommendations on duration of dual
More informationScottish Medicines Consortium
Scottish Medicines Consortium bivalirudin, 250mg powder for concentrate for solution for injection or infusion (Angiox ) No. (516/08) The Medicines Company UK Ltd 07 November 2008 The Scottish Medicines
More informationStephan Windecker Department of Cardiology Swiss Cardiovascular Center and Clinical Trials Unit Bern Bern University Hospital, Switzerland
Advances in Antiplatelet Therapy in PCI and ACS Stephan Windecker Department of Cardiology Swiss Cardiovascular Center and Clinical Trials Unit Bern Bern University Hospital, Switzerland Targets for Platelet
More informationPathology, Pathophysiology, and Epidemiology
Non-ST-Segment Elevation Acute Coronary Syndrome (NSTE-ACS) Vincent J. Pompili, M.D., FACC Professor of Internal Medicine Director of Interventional Cardiology The Ohio State University Richard M. Ross
More informationChapter 15 Glycoprotein IIb/IIIa Antagonists
Chapter 15 Glycoprotein IIb/IIIa Antagonists Introduction - GP IIb/IIIa receptors - Pharmacologic approaches - Preparations and dosages Mechanism of Action Clinical Efficacy - UA / NSTEMI - STEMI - PCI
More informationAnticoagulants in Coronary Artery Disease
Anticoagulants in Coronary Artery Disease L.Veronica Lee, MD KEYWORDS Anticoagulant Acute coronary syndrome Acute myocardial infarction Unstable angina Therapy Acute coronary syndromes, such as unstable
More informationAdults With Diagnosed Diabetes
Adults With Diagnosed Diabetes 1990 No data available Less than 4% 4%-6% Above 6% Mokdad AH, et al. Diabetes Care. 2000;23(9):1278-1283. Adults With Diagnosed Diabetes 2000 4%-6% Above 6% Mokdad AH, et
More information12/18/2009 Resting and Maxi Resting and Max mal Coronary Blood Flow 2
Coronary Artery Pathophysiology ACS / AMI LeRoy E. Rabbani, MD Director, Cardiac Inpatient Services Director, Cardiac Intensive Care Unit Professor of Clinical Medicine Major Determinants of Myocardial
More informationPrevention of Coronary Stent Thrombosis and Restenosis
Prevention of Coronary Stent Thrombosis and Restenosis Seong-Wook Park, MD, PhD, FACC Division of Cardiology, Asan Medical Center University of Ulsan College of Medicine, Seoul, Korea 9/12/03 Coronary
More informationNovel Anticoagulation Therapy in Acute Coronary Syndrome
Novel Anticoagulation Therapy in Acute Coronary Syndrome Soon Jun Hong Korea University Anam Hospital 1 Thrombus Formation Cascade Coagulation Cascade Platelet Cascade TXA2 Aspirin R Inhibitor Fondaparinux
More informationCoronary plaque erosion: a clinical case. Dr. Giampaolo Niccoli, MD, PhD, FESC Institute of Cardiology Catholic University, Rome, Italy
Coronary plaque erosion: a clinical case, MD, PhD, FESC Institute of Cardiology Catholic University, Rome, Italy Coronary plaque erosion: a clinical case B.M. Age: 59 years Sex: female. Cardiological risk
More informationAIMS: CHEST PAIN. Causes of chest pain. Causes of chest pain: Cardiac causes: Acute coronary syndromes pericarditis thoracic aortic dissection
CHEST PAIN Dr Susan Hertzberg Emergency Department Prince of Wales Hospital AIMS: To identify causes of chest pain in patients presenting to the ED. To identify and risk stratify patients presenting with
More informationOUTPATIENT ANTITHROMBOTIC MANAGEMENT POST NON-ST ELEVATION ACUTE CORONARY SYNDROME. TARGET AUDIENCE: All Canadian health care professionals.
OUTPATIENT ANTITHROMBOTIC MANAGEMENT POST NON-ST ELEVATION ACUTE CORONARY SYNDROME TARGET AUDIENCE: All Canadian health care professionals. OBJECTIVE: To review the use of antiplatelet agents and oral
More informationIndications of Coronary Angiography Dr. Shaheer K. George, M.D Faculty of Medicine, Mansoura University 2014
Indications of Coronary Angiography Dr. Shaheer K. George, M.D Faculty of Medicine, Mansoura University 2014 Indications for cardiac catheterization Before a decision to perform an invasive procedure such
More informationUnstable angina and NSTEMI
Issue date: March 2010 Unstable angina and NSTEMI The early management of unstable angina and non-st-segment-elevation myocardial infarction This guideline updates and replaces recommendations for the
More informationManagement of Acute Coronary Syndromes
Management of Acute Coronary Syndromes Objectives 1. To outline the approach in managing a patient who presents with an acute coronary syndrome focusing on anti- thrombotic agents. Jenny Chiu, BScPhm,
More informationPERIOPERATIVE MYOCARDIAL INFARCTION THE ANAESTHESIOLOGIST'S VIEW
PERIOPERATIVE MYOCARDIAL INFARCTION THE ANAESTHESIOLOGIST'S VIEW Bruce Biccard Perioperative Research Group, Department of Anaesthetics 18 June 2015 Disclosure Research funding received Medical Research
More informationUPDATE ON THE MANAGEMENTACUTE CORONARY SYNDROME. DR JULES KABAHIZI, Psc (Rwa) Lt Col CHIEF CONSULTANT RMH/KFH 28 JUNE18
UPDATE ON THE MANAGEMENTACUTE CORONARY SYNDROME DR JULES KABAHIZI, Psc (Rwa) Lt Col CHIEF CONSULTANT RMH/KFH 28 JUNE18 INTRODUCTION The clinical entities that comprise acute coronary syndromes (ACS)-ST-segment
More informationPathology of percutaneous interventions (PCI) in coronary arteries. Allard van der Wal, MD.PhD; Pathologie AMC, Amsterdam, NL
Pathology of percutaneous interventions (PCI) in coronary arteries Allard van der Wal, MD.PhD; Pathologie AMC, Amsterdam, NL Percutaneous Coronary Intervention (PCI) Definition: transcatheter opening of
More informationPercutaneous coronary intervention (PCI), in
ECONOMIC IMPLICATIONS OF THE USE OF DIRECT THROMBIN INHIBITORS IN PERCUTANEOUS CORONARY INTERVENTION David J. Cohen, MD, MSc * ABSTRACT More than 1.2 million percutaneous coronary intervention (PCI) procedures
More informationDEEP VEIN THROMBOSIS (DVT): TREATMENT
DEEP VEIN THROMBOSIS (DVT): TREATMENT OBJECTIVE: To provide an evidence-based approach to treatment of patients presenting with deep vein thrombosis (DVT). BACKGROUND: An estimated 45,000 patients in Canada
More informationSTEMI 2014 YAHYA KIWAN. Consultant Cardiologist Head Of Cardiology Belhoul Specialty Hospital
STEMI 2014 YAHYA KIWAN Consultant Cardiologist Head Of Cardiology Belhoul Specialty Hospital Aspiration Thrombectomy Manual aspiration thrombectomy is reasonable for patients undergoing primary PCI. I
More information